Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71,689 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: lee cw, lee jc, lee h, lee s. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Online ahead of print. Cancer Res. 2022. PMID: 36018295 No abstract available.
Correction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: lee cw, lee jc, lee h, lee s. Cancer Res. 2022 Aug 25:OF1. doi: 10.1158/0008-5472.CAN-22-2377. Online ahead of print. Cancer Res. 2022. PMID: 36006687 No abstract available.
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.
Choi YJ, Kim DS, Hoon Sung Y, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: lee cw, lee jc, lee h, lee s. Cancer Res. 2022 Jun 14:canres.0394.2022-2-3 21:03:12.200. doi: 10.1158/0008-5472.CAN-22-0394. Online ahead of print. Cancer Res. 2022. PMID: 35700239 Retracted.
Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer.
Choi YJ, Lee H, Kim DS, Kim DH, Kang MH, Cho YH, Choi CM, Yoo J, Lee KO, Choi EK, Lee JC, Rho JK. Choi YJ, et al. Among authors: lee ko, lee jc, lee h. Eur J Pharmacol. 2021 Sep 15;907:174298. doi: 10.1016/j.ejphar.2021.174298. Epub 2021 Jul 3. Eur J Pharmacol. 2021. PMID: 34224696
Acidic solvent improves cisplatin action in in-vitro.
Kim Y, Lee HM. Kim Y, et al. Among authors: lee hm. Biochem Biophys Res Commun. 2024 Apr 12;712-713:149936. doi: 10.1016/j.bbrc.2024.149936. Online ahead of print. Biochem Biophys Res Commun. 2024. PMID: 38640736
71,689 results
You have reached the last available page of results. Please see the User Guide for more information.